156 related articles for article (PubMed ID: 12530002)
1. Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein.
Caceres G; Dauphinee MJ; Eisele LE; MacColl R; Mizejewski GJ
Anticancer Res; 2002; 22(5):2817-20. PubMed ID: 12530002
[TBL] [Abstract][Full Text] [Related]
2. Anticancer versus antigrowth activities of three analogs of the growth-inhibitory peptide: relevance to physicochemical properties.
Mizejewski GJ; Eisele L; Maccoll R
Anticancer Res; 2006; 26(4B):3071-6. PubMed ID: 16886636
[TBL] [Abstract][Full Text] [Related]
3. Antiestrogenic and anticancer activities of peptides derived from the active site of alpha-fetoprotein.
Joseph LC; Bennett JA; Kirschner KN; Shields GC; Hughes J; Lostritto N; Jacobson HI; Andersen TT
J Pept Sci; 2009 Apr; 15(4):319-25. PubMed ID: 19189271
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo.
Koshiuka K; Elstner E; Williamson E; Said JW; Tada Y; Koeffler HP
Br J Cancer; 2000 Jan; 82(2):452-8. PubMed ID: 10646904
[TBL] [Abstract][Full Text] [Related]
5. Synthetic peptide derived from alpha-fetoprotein inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimization.
DeFreest LA; Mesfin FB; Joseph L; McLeod DJ; Stallmer A; Reddy S; Balulad SS; Jacobson HI; Andersen TT; Bennett JA
J Pept Res; 2004 May; 63(5):409-19. PubMed ID: 15140158
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide.
Papo N; Seger D; Makovitzki A; Kalchenko V; Eshhar Z; Degani H; Shai Y
Cancer Res; 2006 May; 66(10):5371-8. PubMed ID: 16707464
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of cytotropic heterogeneous molecular lipids (CHML) on human breast cancer xenograft in nude mice.
Zhan Q; Zhao SC; Xu Z
Anticancer Res; 2001; 21(4A):2477-82. PubMed ID: 11724310
[TBL] [Abstract][Full Text] [Related]
8. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo.
Vegesna V; O'Kelly J; Said J; Uskokovic M; Binderup L; Koeffle HP
Anticancer Res; 2003; 23(1A):283-9. PubMed ID: 12680225
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer growth inhibition by delivery of the MDGI-derived peptide P108.
Wang HL; Kurtz A
Oncogene; 2000 May; 19(20):2455-60. PubMed ID: 10828888
[TBL] [Abstract][Full Text] [Related]
10. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
11. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
[TBL] [Abstract][Full Text] [Related]
13. Boc-lysinated-betulonic acid: a potent, anti-prostate cancer agent.
Saxena BB; Zhu L; Hao M; Kisilis E; Katdare M; Oktem O; Bomshteyn A; Rathnam P
Bioorg Med Chem; 2006 Sep; 14(18):6349-58. PubMed ID: 16777417
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
15. Alpha-fetoprotein derived from a human hepatoma prevents growth of estrogen-dependent human breast cancer xenografts.
Bennett JA; Zhu S; Pagano-Mirarchi A; Kellom TA; Jacobson HI
Clin Cancer Res; 1998 Nov; 4(11):2877-84. PubMed ID: 9829755
[TBL] [Abstract][Full Text] [Related]
16. A peptide derived from alpha-fetoprotein inhibits the proliferation induced by estradiol in mammary tumor cells in culture.
Sierralta WD; Epuñan MJ; Reyes JM; Valladares LE; Andersen TT; Bennett JA; Jacobson HI; Pino AM
Oncol Rep; 2008 Jan; 19(1):229-35. PubMed ID: 18097600
[TBL] [Abstract][Full Text] [Related]
17. Targeting breast and prostate cancers through their hormone receptors.
Leuschner C; Hansel W
Biol Reprod; 2005 Nov; 73(5):860-5. PubMed ID: 16033998
[TBL] [Abstract][Full Text] [Related]
18. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.
Ni J; Mai T; Pang ST; Haque I; Huang K; DiMaggio MA; Xie S; James NS; Kasi D; Chemler SR; Yeh S
Clin Cancer Res; 2009 Feb; 15(3):898-906. PubMed ID: 19188160
[TBL] [Abstract][Full Text] [Related]
20. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
